The financials
Tarsus Pharmaceuticals, Inc. by the numbers
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $174M in Q2 2026 (quarter ended June 30, 2026), up 69% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $19M. For the full year FY2025, revenue was $451M (+147% year on year) and net income −$66M. Its largest product in 2023-Q3 was License And Collaboration at $218K, 52% of the disclosed total, just ahead of License And Collaboration Other at 48%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $174M | $103M | +69% |
| Gross profit | $162M | $96M | +68% |
| Operating income | −$20M | −$22M | n/a |
| Net income | −$19M | −$20M | n/a |
| Diluted EPS | −$0.43 | −$0.48 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Collaboration | $218K | 52% |
| License And Collaboration Other | $200K | 48% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $0.00 (-100%)
Segment Latestquarter on quarteryear on year
- License And Collaboration$0.00$0.00QoQ -100%year on year --100%-